The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines

Inclusion Criteria:

• Men and women aged between 19 to 65 years old
• Subjects attaining ≥grade 2 (moderate) in the investigator's rating of the severity of glabellar lines at maximum frown
• Fertile women who have properly agreed to contraception during the clinical trial period
• Subjects who voluntarily sign the informed consent

Exclusion Criteria:

• Subjects who answered 'Yes' any of the C-SSRS questions (only Phase I)
• Subjects with the general neuromuscular synaptic disorder(e.g. Myasthenia gravis, Lambert-Eaton syndrome)
• Subjects who suffer from muscle weakness or paralysis in the forehead area
• Subjects with infection, skin disorders, or scars at the glabellar region.
• Subjects with noticeable facial asymmetry
• Subjects with allergy or hypersensitivity to the botulinum toxin or their components
• Subjects who have taken Anti-Coagulant, Anti-Platelet agent, Aspirin and NSAIDs within 7 days prior to administration of the investigational drug
• Subjects who were injected facial with botulinum toxin within the past 6 months or whose dose exceeds 200 U for the whole body
• Subjects with previous treatment of Face Lifting, Permanent Implant, and/or Filler in the glabellar region
• Subjects who are participating in other clinical trials or have participated in other clinical trials within 4 weeks of the screening date.
• A history of drug or alcohol abuse
• Fertile women and men who have plans to conceive during pregnancy, breastfeeding and clinical trials or who do not agree to appropriate contraception
• Subjects who are not eligible for this study based on the judgment of an investigator